Nivolumab as Maintenance Therapy Following Platinum-Based Chemotherapy in EGFR-mutant Lung Cancer Patients After TKI Failure

被引：0
|
作者：
Kim, J. [1 ,2 ]
Choi, C. -M. [1 ]
Lee, J. C. [1 ]
Ji, W. [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
[2] Kyung Hee Univ, Med Ctr, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer; Nivolulmab; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.02
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [1] Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial
    Kim, Jiwon
    Choi, Chang-Min
    Ji, Wonjun
    Lee, Jae Cheol
    THORACIC CANCER, 2023, 14 (31) : 3080 - 3088
  • [2] The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma
    Onodera, K.
    Aokage, K.
    Wakabayashi, M.
    Ikeno, T.
    Suzuki, J.
    Miyoshi, T.
    Tane, K.
    Smajima, J.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S199 - S200
  • [3] The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients
    Ebisudani, Toshiki
    Nakashima, Kei
    Misawa, Masafumi
    Tokumoto, Akiko
    Nemoto, Masahiro
    Tsuzuki, Ryuta
    Suzuki, Fumi
    Yamawaki, Satoshi
    Otsuki, Ayumu
    Noma, Satoshi
    Aoshima, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1208 - S1209
  • [4] Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors
    Wu, S. G.
    Huang, Y. L.
    Ho, C. C.
    Liao, W. Y.
    Tsai, T. H.
    Yang, J. C. H.
    Shih, J. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S57 - S57
  • [5] Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
    Marmarelis, M. E.
    Lee, S. -H.
    Spira, A. I.
    Ou, S. -H. I.
    Waqar, S.
    Li, S.
    Thayu, M.
    Knoblauch, R. E.
    Bauml, J. M.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S68 - S68
  • [6] Neoadjuvant nivolumab in combination with platinum-based chemotherapy for operable lung cancer
    Hekmat, Khosro
    Bruns, Christiane J.
    CHIRURGIE, 2022,
  • [7] Efficacy analysis of immunotherapy-based combinations for patients with EGFR-mutant advanced non-small cell lung cancer after TKI failure
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ONCOLOGY LETTERS, 2024, 28 (05)
  • [8] Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance
    Ding, Jianghua
    Ding, Xinjing
    Leng, Zhaohui
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 187 - 198
  • [9] Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small-cell lung cancer after TKI therapy
    Yu, Li
    Bazhenova, Lyudmila
    Gold, Kathryn
    Tran, Lisa
    Hilburn, Van
    Vu, Peter
    Patel, Sandip Pravin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (03) : 452 - 461
  • [10] CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
    Lee, Alexandria T. M.
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2023, 14 : 41 - 46
12345